Group 1 - The company has decided to reappoint Zhongshun Zhonghuan Accounting Firm as its auditor for the year 2025, pending approval from the shareholders' meeting [1][6][7] - Zhongshun Zhonghuan has been recognized for its diligent and objective auditing practices since its appointment, demonstrating the capability to provide auditing services for listed companies [1][2] - The audit fees for the 2025 annual audit are set at 720,000 yuan, while the internal control audit fees are set at 280,000 yuan, with no changes in the fees compared to the previous year [5][6] Group 2 - Zhongshun Zhonghuan was established in 1987 and is one of the first large accounting firms approved to conduct securities and futures-related business audits in China [2] - As of the end of 2024, Zhongshun Zhonghuan has 216 partners and 1,304 registered accountants, with 723 of them having signed audit reports for securities services [2][3] - The firm has audited 244 listed companies across various industries, including manufacturing, wholesale and retail, real estate, and more, with a total audited revenue of approximately 2.17 billion yuan in 2024 [2][3]

Group 1 - The company held its 16th meeting of the 6th Supervisory Board on June 6, 2025, in Haikou, where all three supervisors attended, meeting legal requirements [1] - The Supervisory Board approved the reappointment of Zhongshun Zhonghuan Accounting Firm as the company's auditing institution for the year 2025, with an audit fee of 720,000 yuan, and for internal control auditing at 280,000 yuan [1] - The appointment period for the auditing firm is one year, effective from the approval date at the 2024 annual general meeting [1] Group 2 - The proposal for the reappointment of the auditing firm will be submitted for review at the 2024 annual general meeting [2] - The company plans to purchase liability insurance for directors, supervisors, and senior management to enhance its risk management system and reduce operational risks [2] - The review process for the liability insurance proposal complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [2]

关于购买董监高责任险的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 康芝药业股份有限公司（以下简称"公司"） 于 2025 年 6 月 6 日召开第 六届董事会第十九次会议、第六届监事会第十六次会议，审议通过了《关于购买 董监高责任险的议案》，为进一步完善公司风险管理体系，降低公司运营风险， 促进公司董事、监事及高级管理人员在各自职责范围内更充分地发挥决策、监督 和管理的职能，保障公司和投资者的权益，根据《上市公司治理准则》等法律法 规，公司拟为公司及全体董事、监事和高级管理人员购买责任保险。现将具体情 况公告如下： 一、保险方案 证券代码：300086 证券简称：康芝药业 公告编号：2025-029 1、投保人：康芝药业股份有限公司。 康芝药业股份有限公司 2、被保险人：公司及全体董事、监事和高级管理人员（具体以最终签订的保 险合同为准）。 二、相关授权事宜 为顺利推进上述事项实施，提高决策效率，公司董事会提请股东会授权公司管 理层在上述权限内办理董监高责任险购买的相关事宜（包括但不限于确定被保险 人范围、保险公司；保险金额、保险费用及其他保险条款；选择及 ...

续聘2025年度审计机构事项尚需提交公司股东大会审议通过，现将相关事宜公 告如下： 一、拟聘请会计师事务所事项的情况说明 证券代码：300086 证券简称：康芝药业 公告编号：2025-027 康芝药业股份有限公司 关于聘请公司 2025 年度审计机构的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2025年6月6日，康芝药业股份有限公司（以下简称"公司"）第六届董事会第十 九次会议及第六届监事会第十六次审议通过了《关于聘请公司2025年度审计机构 的议案》，同意公司续聘中审众环会计师事务所（特殊普通合伙）（以下简称"中 审众环"）为公司2025年度审计机构，聘期一年，自公司2024年度股东大会审议通 过之日起生效。 中审众环会计师事务所（特殊普通合伙）是一家具备证券、期货相关业务审计 从业资格的审计机构，具备为上市公司提供审计服务的经验和能力。公司聘任中审 众环为公司审计机构以来，其工作勤勉尽责，坚持以公允、客观的态度进行独立审 计，认真地完成了公司各项审计工作。 二、拟聘请会计师事务所的基本信息 （一）机构信息 1.基本信息 （1）机构名称：中审众环会计 ...

证券代码：300086 证券简称：康芝药业 公告编号：2025-028 康芝药业股份有限公司 关于召开 2024 年度股东大会通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《中华人民共和国公司法》及《公司章程》的有关规定，经康芝药业股份有限公司 （以下简称"公司"）第六届董事会第十九次会议审议通过，公司决定于 2025 年 6 月 30 日 （星期一）在海口国家高新技术产业开发区药谷工业园药谷三路 6 号公司会议室召开 2024 年 度股东大会，本次股东大会将采取现场和网络投票相结合的表决方式。根据相关规定，现就 本次股东大会相关信息公告如下： 一、本次股东大会召开的基本情况 1、股东大会届次：2024 年度股东大会。 2、股东大会的召集人：公司董事会。 3、会议召开的合法、合规性：本次股东大会召开经公司第六届董事会第十九次会议审议 通过，召集程序符合有关法律、行政法规、部门规章、规范性文件和公司章程的规定。 4、会议召开时间： 现场会议召开时间：2025 年 6 月 30 日（星期一）下午 15:00 开始。 （ 2 ） 网 络 投 票 ： ...

证券代码：300086 证券简称：康芝药业 公告编号：2025-026 康芝药业股份有限公司 第六届监事会第十六次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 康芝药业股份有限公司（以下简称"康芝药业"或"公司"）第六届监事会第十六次会议 于2025年6月6日在海口国家高新技术产业开发区药谷工业园药谷三路6号公司会议室以现场 表决的方式召开。会议通知于2025年5月26日分别以邮件、电话和书面的方式发出，应出席本 次会议监事3名，实际出席监事3名，符合《中华人民共和国公司法》《公司章程》等法律法规 的规定。本次会议由公司监事会主席高洪常先生主持。出席会议的全体监事经过认真审议， 通过了以下议案： 1、以 3 票赞同、0 票反对、0 票弃权审议通过了《关于聘请公司 2025 年度审计机构的议 案》。 经审核，监事会认为：同意公司续聘中审众环会计师事务所（特殊普通合伙）为公司 2025 年度审计机构，审计费用为 72 万元；同时同意续聘中审众环会计师事务所（特殊普通合伙） 为公司 2025 年度内部控制审计机构，审计费用为 28 万元。聘任期限为一年，自 ...

证券代码：300086 证券简称：康芝药业 公告编号：2025-025 康芝药业股份有限公司 第六届董事会第十九次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 康芝药业股份有限公司（以下简称"公司"）第六届董事会第十九次会议于 2025 年 6 月 6 日在海口国家高新技术产业开发区药谷工业园药谷三路 6 号会议室以现 场及通讯表决的方式召开。会议通知于 2025 年 5 月 26 日分别以邮件、电话等方 式发出，应出席本次会议董事 9 名，实际出席董事 9 名。会议由董事长洪江游先生 主持，公司监事及相关高级管理人员列席了本次会议。会议的召开符合《中华人民 共和国公司法》《公司章程》等法律法规的规定。 经与会董事认真审议并表决，通过了以下议案： 1、以 9 票赞同、0 票反对、0 票弃权审议通过了《关于聘请公司 2025 年度审 计机构的议案》。 经董事会审议通过，同意公司续聘中审众环会计师事务所（特殊普通合伙）为 公司 2025 年度审计机构，审计费用为 72 万元；同时同意续聘中审众环会计师事务 所（特殊普通合伙）为公司 2025 年度内部控制 ...

Group 1: Comac Medical Group Acquisition - Comac Medical Group, supported by EdgeCap Partners, announced the acquisition of ILIFE Consulting, a specialized CRO based in Paris, focusing on oncology, rare diseases, and complex early-stage biotech clinical trials [3] - The acquisition enhances Comac's presence in Western Europe, complementing its recent expansions in the UK, Germany, and the US [3] - ILIFE's CEO, Marina Iché, will continue to lead the company and become a significant shareholder, ensuring continuity in corporate culture and service [3] - The acquisition strengthens Comac's technical and service capabilities in early clinical trials, increasing its competitiveness in attracting emerging biotech clients [3] - The growing European biopharmaceutical innovation landscape positions Comac as a preferred clinical R&D outsourcing partner for small and medium-sized biotech companies [3] - EdgeCap Partners' strategy of building regional leaders through platform acquisitions in the CRO industry is noteworthy [3] Group 2: Kelun Pharmaceutical - Kelun Pharmaceutical has transitioned from traditional infusion business to innovative drugs and synthetic biology, with strong stock performance and high market expectations [2] - Despite a decline in revenue and profit in Q1 2025, the stock price continued to rise, indicating market confidence in its future [2] - The company faces challenges with its TROP2 ADC drug due to competition from Gilead's products and reliance on a single client for its innovative drug collaborations [4] Group 3: Shanghai Public Hospital Salary Reform - Shanghai's health commission announced a pilot program for annual salary reform in public hospitals, starting with Zhongshan Hospital and Ruijin Hospital [3] - The reform aims to optimize salary structures and may expand to cover doctors and other medical staff, shifting incentives towards long-term performance [3] - DRG and DIP reforms are expected to encourage medical institutions to focus on treatment quality rather than quantity, benefiting innovative and effective drugs [3] Group 4: Cigna and Novo Nordisk Agreement - Cigna's Evernorth has reached an agreement with Novo Nordisk and Eli Lilly to significantly reduce prices for GLP-1 weight loss drugs, benefiting employers and employees [4] - The agreement is expected to provide a 30-50% discount for employers, aligning with the US government's ongoing negotiations for Medicare discounts [4] - Employee out-of-pocket costs will be capped at $200/month, enhancing drug accessibility compared to direct purchase prices [4] Group 5: Domestic Electric Vehicle Sales - In April, the penetration rate of new energy vehicles exceeded 51.7%, with a notable increase in the share of A00 and A0 class small electric vehicles, indicating consumer sensitivity to price [5] - The mid-to-low-end electric vehicle market is expected to expand rapidly, benefiting battery material companies and midstream suppliers [5] - BYD maintained a leading market share of 32.9%, while Tesla's Model Y saw a significant sales decline of 30.7%, reflecting challenges in pricing and product cycles [5] - Midstream material companies are likely to benefit directly from the increase in sales volume as the market shifts towards cost-sensitive models [5][6]

Group 1: Investor Relations Activity - The investor relations activity was conducted as an earnings briefing on May 13, 2025, from 14:00 to 17:00 via an online platform [2] - The meeting was attended by key company representatives including the Chairman, independent directors, and financial executives [2] Group 2: Product Launch and Development - The company is preparing to launch the product "Reyaning Granules" by July to August 2025 [2] - The company emphasizes its commitment to the development of traditional Chinese medicine, focusing on secondary development of existing products [2] Group 3: Current Product Offerings - The company currently produces and sells various traditional Chinese medicine products, including: - Zhenrong Dan Decoction - Cough Orange Granules - Antiviral Oral Liquid - Cold and Heat Relief Granules - Children's Heat Relief Granules - And several others [3]

本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为推动辖区上市公司进一步建立董事会与投资者的良好沟通机制，让投资者 更准确地读懂年度报告、更全面地了解上市公司，切实提高上市公司透明度和治 理水平，海南证监局将与深圳市全景网络有限公司、海南上市公司协会联合举办 "2024 年度海南辖区上市公司业绩说明会暨投资者集体接待日"活动，活动时 间为 2025 年 5 月 13 日 14:00-17:00，平台登陆地址为：https://rs.p5w.net。 证券代码：300086 证券简称：康芝药业 公告编号：2025-024 康芝药业股份有限公司 关于参加"2024 年度海南辖区 上市公司业绩说明会暨投资者集体接待日"的公告 康芝药业股份有限公司 董 事 会 2025 年 5 月 7 日 届时，康芝药业股份有限公司主要高管人员将参加本次活动，通过网络在线 交流形式，就公司 2024 年年报披露、财务数据、公司治理、内部控制、发展战 略、经营状况、现金分红、重大事项、可持续发展等投资者所关心的问题，与投 资者进行"一对多"形式的沟通与交流。欢迎广大投资者踊跃参与。 特此公告 ...